M1A.45
Other secondary chronic gout, hip
Clinical Classification Guidelines
Medical Intelligence & Overview
Other secondary chronic gout of the hip, classified under ICD-10 code M1A.45, is a long-term condition characterized by the buildup of uric acid crystals in the hip joint. This form of gout differs from primary gout, which is typically caused by an inherited disturbance in uric acid metabolism. Secondary gout arises due to other underlying health issues that influence uric acid levels and joint health. The chronic nature of this condition indicates ongoing joint damage and recurrent flare-ups that may severely impact mobility and quality of life if left unmanaged.
Causes & Symptoms
Clinical Causes: Chronic kidney disease leading to impaired uric acid excretion Use of certain medications such as diuretics or immunosuppressants Metabolic disorders affecting purine metabolism Heavy alcohol consumption Obesity contributing to increased uric acid production Diet rich in purines, including red meats, shellfish, and sugary beverages Other medical conditions causing increased cell turnover or reduced uric acid clearance
Key Symptoms: Persistent joint pain and tenderness in the hip Swelling and redness around the affected joint Limited range of motion and stiffness in the hip Chronic discomfort or aching sensation Recurrent gout attacks that become more frequent over time Possible formation of tophi—urate crystal deposits visible under the skin
Diagnostic & Treatment
Diagnosis Path: Diagnosis of other secondary chronic gout of the hip involves a combination of medical history assessment, physical examination, and diagnostic tests. Blood tests measuring serum uric acid levels may indicate hyperuricemia, although levels can sometimes be normal during an attack. Imaging studies, such as ultrasound or dual-energy CT scans, can help visualize urate crystal deposits and joint damage. In some cases, joint aspiration is performed to extract fluid for analysis, confirming the presence of monosodium urate crystals.
Treatment Protocols: Managing this condition focuses on reducing inflammation, preventing flare-ups, and lowering uric acid levels to prevent further joint damage. Common approaches include: - Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids during acute attacks - Uric acid-lowering therapies like allopurinol or febuxostat for long-term management - Lifestyle modifications, including a balanced diet low in purines, weight management, and alcohol reduction - Regular monitoring of uric acid levels to adjust treatment plans accordingly - Physical therapy and supportive measures to maintain joint function and reduce stiffness It is essential to work closely with healthcare providers to develop an individualized management plan suited to the patient’s specific health status and needs.
Clinical Advice & FAQs
Billing Guidance
Is M1A.45 a billable ICD-10 code?
Yes, M1A.45 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M1A.45?
Clinical documentation must specify the nature of Other secondary chronic gout, hip and any associated comorbidities for accurate reporting.
Cite this Clinical Reference